Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;97(5):e13261.
doi: 10.1111/sji.13261. Epub 2023 Mar 6.

Polysaccharides and glycolipids of Mycobacterium tuberculosis and their induced immune responses

Affiliations
Free article
Review

Polysaccharides and glycolipids of Mycobacterium tuberculosis and their induced immune responses

Yang Gong et al. Scand J Immunol. 2023 May.
Free article

Abstract

Tuberculosis (TB) is a chronic infectious disease mainly caused by Mycobacterium tuberculosis (M. tuberculosis). The structures of polysaccharides and glycolipids at M. tuberculosis cell wall vary among different strains, which affect the physiology and pathogenesis of mycobacteria by activating or inhibiting innate and acquired immunity. Among them, some components such as lipomannan (LM) and lipoarabinomannan (LAM) activate innate immunity by recognizing some kinds of pattern recognition receptors (PRRs) like Toll-like receptors, while other components like mannose-capped lipoarabinomannan (ManLAM) could prevent innate immune responses by inhibiting the secretion of pro-inflammatory cytokines and maturation of phagosomes. In addition, many glycolipids can activate natural killer T (NKT) cells and CD1-restricted T cells to produce interferon-γ (IFN-γ). Furthermore, humoral immunity against cell wall components, such as antibodies against LAM, plays a role in immunity against M. tuberculosis infection. Cell wall polysaccharides and glycolipids of M. tuberculosis have potential applications as antigens and adjuvants for novel TB subunit vaccines.

Keywords: Mycobacterium tuberculosis; adaptive immunity; glycolipids; innate immunity; polysaccharides; subunit vaccine.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Furin J, Cox H, Pai M. Tuberculosis. Lancet (London, England). 2019;393(10181):1642‐1656.
    1. Sia JK, Rengarajan J. Immunology of mycobacterium tuberculosis infections. Microbiol Spectr. 2019;7(4).
    1. Fatima S, Kumari A, Das G, Dwivedi VP. Tuberculosis vaccine: a journey from BCG to present. Life Sci. 2020;252:117594.
    1. Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.
    1. Achkar JM, Prados‐Rosales R. Updates on antibody functions in mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. Curr Opin Immunol. 2018;53:30‐37.

MeSH terms

LinkOut - more resources